iloprost has been researched along with Hodgkin-Disease* in 2 studies
2 other study(ies) available for iloprost and Hodgkin-Disease
| Article | Year |
|---|---|
Bleomycin-induced Raynaud's phenomenon after single-dose exposure: risk factors and treatment with intravenous iloprost infusion.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Doxorubicin; Fingers; Hodgkin Disease; Humans; Iloprost; Infusions, Intravenous; Male; Middle Aged; Multimodal Imaging; Necrosis; Positron-Emission Tomography; Raynaud Disease; Remission Induction; Risk Factors; Tomography, X-Ray Computed; Treatment Outcome; Vasodilator Agents; Vinblastine | 2013 |
Efficiency of iloprost treatment for chemotherapy-associated osteonecrosis after childhood cancer.
The risk of developing avascular osteonecrosis (AVN) after chemotherapy is age related and, at up to 17% of all treated patients, relatively high.. In a prospective study, 8 patients (4 male, 4 female, 14.3+/-4.9 years old) were treated for symptomatic chemotherapy-associated AVN with intravenous infusion of iloprost. Association Research Circulation Osseus (ARCO) stages I-IV in 37 bones (25 joints) were treated.. Follow-up was 20.8+/-17 months (range: 6-53 months). No serious adverse reactions due to the infusion with iloprost were recorded. Pain levels were lower and functional outcome measured as Harris Hip and Knee Society Scores improved by the latest follow up.. Our current data confirm the findings of other investigators that healing of advanced stages of AVN is not possible, but that in early stages of AVN, pain relief and an improvement of joint function can be achieved by iloprost. Topics: Adolescent; Adult; Age Factors; Child; Female; Hodgkin Disease; Humans; Iloprost; Male; Osteonecrosis; Pain; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Prospective Studies; Treatment Outcome; Vasodilator Agents; Young Adult | 2009 |